Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial" is generating significant coverage in the Health category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include kkam.com, DongA Science, Medical Xpress and New York Post. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 4h ago.
Quick answers
Why is "Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- A new drug allows you to lose your gut without Ozempic or surgery! kkam.com · 1d ago
- Next-generation obesity drug CBL-514 enters phase 3, destroying fat cells without rebound DongA Science · 1d ago
- New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells Medical Xpress · 1d ago
- New weight-loss drug could give you a ‘flatter stomach’ in mere weeks New York Post · 1d ago
- Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial Medscape · 1d ago
Topics
Related trends
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
“Survivor” Contestant Cuts off Part of His Thumb with a Machete in Gory On-Screen Injury
1 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Paramount Cuts Pricing on $30 Billion High-Grade Bond Sale for Warner Bros. Deal
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Disney Cuts Hundreds More Jobs in New Round of Layoffs as Corporate Streamlining Casualties Mount
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
His Last Novel Won the Pulitzer. This One Fails to Launch.
Pulitzer winner Hernan Diaz returns with a new book, sparking intense critical debate across major cultural outlets.
Can a Drug Reverse Age-Related Muscle Weakness?
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.